Here are four things to know:
1. VANTRELA ER is intended to manage severe pain that may require long-term opioid treatment.
2. VANTRELA ER is an extended-release formulation of hydrocodone bitartrate with Teva’s proprietary abuse deterrence technology.
3. The committees also voted that, if approved, Teva Pharmaceutical’s should label the medication an “abuse-deterrent product.”‘
4. While the FDA is not bound by the committees, it will take their decision into consideration.
More articles on ASC quality:
Planetree selects Laser Spine Institute as 1st ASC to participate in patient-centered outcomes research project: 5 points
US surgeons use Stryker’s SurgiCount Safety Sponges in 10M procedures: 5 notes
More than 1k infants linked to Zika & microcephaly — 5 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.